AfricaRegulatory
African Pharmaceutical Regulatory Intelligence
NORETHISTERONE ENANTHATE
5 registrations across 4 African markets— 4 active
Markets with NORETHISTERONE ENANTHATE
Recent registrations
| Brand / Product | Market | Holder | Status | Expires |
|---|---|---|---|---|
| NORISTERAT Solution For Injection | 🇰🇪Kenya | Bayer Pharma AG | active | Feb 2031 |
| PRIMOLUT N TABLET; ORAL | 🇿🇼Zimbabwe | BAYER (PTY) LIMITED | active | Dec 2027 |
| NUR - ISTERATE SOLUTION; INJECTION | 🇿🇼Zimbabwe | BAYER (PTY) LTD | active | Dec 2027 |
| NORISTERAT 200 MG/ML SOLUTION FOR INJECTION SOLUTION FOR INJECTION | 🇲🇼Malawi | — | expired | Mar 2025 |
| NUR-ISTERATE | 🇿🇦South Africa | Bayer (Pty) Ltd û Isando | active | Jan 1900 |
NORETHISTERONE ENANTHATE in Africa — Regulatory Overview
NORETHISTERONE ENANTHATE is registered across 4 African markets with 5 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Zimbabwe, Kenya, Malawi, South Africa. AfricaRegulatory refreshes this data daily from official government sources.
Of the 5 registrations, 4 (80%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.